Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

first oral therapy

- PMLiVE

Novartis reports death of two patients treated with Zolgensma

The company has notified health authorities in markets where the drug is sold and has informed relevant healthcare professionals

- PMLiVE

Roche’s Xofluza issued FDA approval to treat influenza in children aged five years and older

It is the first and only single-dose oral medicine for this indication in children as young as five

- PMLiVE

Roche and Cend Therapeutics to evaluate pancreatic cancer combination therapy

Pancreatic cancer is the third leading cause of cancer-related deaths, with over 430,000 deaths each year

- PMLiVE

Roche’s Tecentriq demonstrates positive phase 3 results as a subcutaneous injection

Subcutaneously administering Tecentriq reduced the time needed for treatment compared to standard IV infusion

- PMLiVE

Roche’s Vabysmo recommended for EU approval by CHMP for sight loss

If approved, Vabysmo would be the first mechanism of action for nAMD and DME in the EU for over ten years

- PMLiVE

Roche’s diagnostic test for Alzheimer’s receives FDA Breakthrough Device Designation

Alzheimer's affects more than 55 million people globally and is the most common form of dementia

- PMLiVE

NICE recommends Rhythm Pharmaceuticals’ Imcivree for severe obesity and hyperphagia

The treatment will be funded and available for use within 90 days in the NHS

- PMLiVE

Bristol Myers Squibb announces NICE recommendation for Opdivo plus Yervoy to treat unresectable malignant pleural mesothelioma

The treatment combination is the first immunotherapy of its kind in over ten years to be made available via the NHS

- PMLiVE

Roche announces two-year data confirming Vabysmo improves neovascular age-related macular degeneration

The data showed, after two years, that 60% of patients treated with Vabysmo could be treated every four months, compared with 45% in year one

- PMLiVE

NICE recommends Novartis’ Piqray in combination with Faslodex for advanced breast cancer patients

Around 2,800 breast cancer patients in England and Wales could benefit from the treatment

- PMLiVE

Bristol Myers Squibb’s Opdivo given NICE recommendation for urothelial cancer treatment

The treatment will be available on the NHS as an adjuvant treatment for those at high-risk of recurrence

- PMLiVE

Roche’s Lunsumio granted Priority Review by FDA for people with relapsed or refractory follicular lymphoma

If approved, this could be the first such antibody approved by the FDA for the treatment of any type of non-Hodgkin lymphoma

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links